What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Oral Health · related questions CL0289

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

Cardiovascular events · People with periodontitis and metabolic syndrome (no CVD; primary prevention)

It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes all cardiovascular events compared with supragingival scaling (plus placebo) (very low certainty).

1 finding from 1 review

Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
12 months
Peto OR 7.77 [1.07, 56.1]
1 study · 165 participants
Very low

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

All CVD-related death · People with periodontitis and metabolic syndrome (no CVD; primary prevention)

It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes all CVD-related death compared with supragingival scaling (plus placebo) (very low certainty).

1 finding from 1 review

Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
12 months
Peto OR 7.48 [0.15, 376.98]
1 study · 165 participants
Very low

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

All‐cause death · People with periodontitis and metabolic syndrome (no CVD; primary prevention)

It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes all-cause death compared with supragingival scaling (plus placebo) (very low certainty).

1 finding from 1 review

Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
12 months
Peto OR 7.48 [0.15, 376.98]
1 study · 165 participants
Very low

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

CRP (mg/dL) at end of study · People with periodontitis and metabolic syndrome (no CVD; primary prevention)

1 finding from 1 review

Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
12 months
beta coefficient -0.002 [-0.19, 0.20]
1 study
Very low

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

Fibrinogen · People with periodontitis and metabolic syndrome (no CVD; primary prevention)

1 finding from 1 review

Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
12 months
beta coefficient 10.9 [-12.0, 33.8]
1 study
Very low